Relieves ocular itching due to seasonal allergic conjunctivitis. ANDA 205190, held by Eugia Pharma. Ketorolac Tromethamine.
As of Nov 21, 2026, ANDA 205190 (Ketorolac Tromethamine), held by Eugia Pharma, was first approved by FDA on Dec 3, 2020, with 0 approved supplements and 0 published complete response letters.
Ketorolac tromethamine ophthalmic solution is indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. Ketorolac tromethamine ophthalmic solution is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. Ketorolac tromethamine ophthalmic solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for: The temporary relief of ocular itching due to seasonal allergic conjunctivitis. The treatment of inflammation following cataract surgery.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 3, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ketorolac Tromethamine0.5% · solution/drops;ophthalmic | Ketorolac Tromethamine | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters